A breakthrough in the understanding of crystal-associated arthritides has been the recognition of the role of inflammasome and IL-1β in mediating crystal-induced inflammation.24 Indeed, anti-IL-1 therapies, such as the recombinant IL-1 receptor antagonist anakinra, have been effective for the treatment of refractory gout.25 Regarding CPPD arthritis there are only a few case reports, case series and observational studies5,26–33 supporting the use of anakinra. This evidence concerns the gene IL1B and gout.